RASSF1A protein expression and correlation with clinicopathological parameters in renal cell carcinoma

BMC Urology

Volumn 8, Issue 1, 2008, Pages

  Tezval, Hossein ^a   Merseburger, Axel S ^a   Matuschek, Ira ^a   Machtens, Stefan ^b   Kuczyk, Markus A ^a   Serth, Jürgen ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Marien Krankenhaus   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RASSF1 PROTEIN, HUMAN; TUMOR MARKER; TUMOR PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; CORRELATION ANALYSIS; EPITHELIUM CELL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; KIDNEY TUMOR; METABOLISM; MIDDLE AGED; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STATISTICS;

FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; STATISTICS AS TOPIC; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 54449095238     PISSN: 14712490     EISSN: 14712490     Source Type: Journal    
DOI: 10.1186/1471-2490-8-12     Document Type: Article

References (32)

1. Evaluation of the 3p21.3 tumour-suppressor gene cluster. LB Hesson WN Cooper F Latif, Oncogene 2007 26 52 7283 7301 10.1038/sj.onc.1210547 17533367
2. Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma. B Zbar H Brauch C Talmadge M Linehan, Nature 1987 327 6124 721 724 10.1038/327721a0 2885753
3. The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis. K Dreijerink E Braga I Kuzmin L Geil FM Duh D Angeloni B Zbar MI Lerman EJ Stanbridge JD Minna, Proc Natl Acad Sci USA 2001 98 13 7504 7509 11390984 10.1073/pnas.131216298
4. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma. C Morrissey A Martinez M Zatyka A Agathanggelou S Honorio D Astuti NV Morgan H Moch FM Richards T Kishida, Cancer Res 2001 61 19 7277 7281 11585766
5. Hypermethylation of the CpG island of the RASSF1A gene in ovarian and renal cell carcinomas. JH Yoon R Dammann GP Pfeifer, Int J Cancer 2001 94 2 212 217 10.1002/ijc.1466 11668500
6. Molecular profiling and classification of sporadic renal cell carcinoma by quantitative methylation analysis. ML Gonzalgo S Yegnasubramanian G Yan CG Rogers TL Nicol WG Nelson CP Pavlovich, Clin Cancer Res 2004 10 21 7276 7283 10.1158/1078-0432.CCR-03-0692 15534102
7. RASSF1A promoter methylation and expression analysis in normal and neoplastic kidney indicates a role in early tumorigenesis. I Peters K Rehmet N Wilke M Kuczyk J Hennenlotter T Eilers S Machtens U Jonas J Serth, Mol Cancer 2007 6 1 49 17634119 10.1186/1476-4598-6-49
8. Role of the Ras-association domain family 1 tumor suppressor gene in human cancers. A Agathanggelou WN Cooper F Latif, Cancer Res 2005 65 9 3497 3508 10.1158/0008-5472.CAN-04-4088 15867337
9. The scaffold protein CNK1 interacts with the tumor suppressor RASSF1A and augments RASSF1A-induced cell death. S Rabizadeh RJ Xavier K Ishiguro J Bernabeortiz M Lopez-Ilasaca A Khokhlatchev P Mollahan GP Pfeifer J Avruch B Seed, J Biol Chem 2004 279 28 29247 29254 10.1074/jbc.M401699200 15075335
10. Expression of RASSF1A, an epigenetically silenced tumor suppressor, overcomes resistance to apoptosis induction by interferons. FJ Reu DW Leaman RR Maitra SI Bae L Cherkassky MW Fox DR Rempinski N Beaulieu AR MacLeod EC Borden, Cancer Res 2006 66 5 2785 2793 16510600 10.1158/0008-5472.CAN-05-2303
11. RASSF1A, the new guardian of mitosis. E Mathe, Nat Genet 2004 36 2 117 118 10.1038/ng0204-117 14752520
12. The tumour suppressor RASSF1A regulates mitosis by inhibiting the APC-Cdc20 complex. MS Song SJ Song NG Ayad JS Chang JH Lee HK Hong H Lee N Choi J Kim H Kim, Nature cell biology 2004 6 2 129 137 10.1038/ncb1091 14743218
13. Depletion of the Ras association domain family 1, isoform A-associated novel microtubule-associated protein, C19ORF5/MAP1S, causes mitotic abnormalities. A Dallol WN Cooper F Al-Mulla A Agathanggelou ER Maher F Latif, Cancer Res 2007 67 2 492 500 10.1158/0008-5472.CAN-06-3604 17234756
14. Involvement of the RASSF1A tumor suppressor gene in controlling cell migration. A Dallol A Agathanggelou S Tommasi GP Pfeifer ER Maher F Latif, Cancer Res 2005 65 17 7653 7659 16140931
15. Tumor susceptibility of Rassf1a knockout mice. S Tommasi R Dammann Z Zhang Y Wang L Liu WM Tsark SP Wilczynski J Li M You GP Pfeifer, Cancer Res 2005 65 1 92 98 15665283
16. Promoter hypermethylation profile of kidney cancer. E Dulaimi I Ibanez de Caceres RG Uzzo T Al-Saleem RE Greenberg TJ Polascik JS Babb WE Grizzle P Cairns, Clin Cancer Res 2004 10 12 Pt 1 3972 3979 10.1158/1078-0432.CCR-04-0175 15217927
17. Hypermethylation of the RASSF1A tumor suppressor gene in Japanese clear cell renal cell carcinoma. K Tokinaga H Okuda A Nomura S Ashida M Furihata T Shuin, Oncol Rep 2004 12 4 805 810 15375503
18. Age-related methylation of tumor suppressor and tumor-related genes: an analysis of autopsy samples. T Waki G Tamura M Sato T Motoyama, Oncogene 2003 22 26 4128 4133 10.1038/sj.onc.1206651 12821947
19. Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma. Y Tomizawa T Kohno H Kondo A Otsuka M Nishioka T Niki T Yamada A Maeshima K Yoshimura R Saito, Clin Cancer Res 2002 8 7 2362 2368 12114441
20. Value of p16INK4a and RASSF1A promoter hypermethylation in prognosis of patients with resectable non-small cell lung cancer. J Wang JJ Lee L Wang DD Liu C Lu YH Fan WK Hong L Mao, Clin Cancer Res 2004 10 18 Pt 1 6119 6125 10.1158/1078-0432.CCR-04-0652 15447998
21. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers. N Yanagawa G Tamura H Oizumi N Kanauchi M Endoh M Sadahiro T Motoyama, Lung Cancer 2007 17606310
22. RASSF1A is not appropriate as an early detection marker or a prognostic marker for non-small cell lung cancer. N Choi DS Son I Song HS Lee YS Lim MS Song DS Lim J Lee H Kim J Kim, Int J Cancer 2005 115 4 575 581 10.1002/ijc.20916 15700308
23. Rapid and large-scale transition of new tumor biomarkers to clinical biopsy material by innovative tissue microarray systems. M Mengel H Kreipe R von Wasielewski, Appl Immunohistochem Mol Morphol 2003 11 3 261 268 12966354
24. TNM staging of renal cell carcinoma: Workgroup No. 3. Union International Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). P Guinan LH Sobin F Algaba F Badellino S Kameyama G MacLennan A Novick, Cancer 1997 80 5 992 993 10.1002/(SICI)1097-0142(19970901)80:5<992::AID-CNCR26>3. 0.CO;2-Q 9307205
25. Alteration of subcellular and cellular expression patterns of cyclin B1 in renal cell carcinoma is significantly related to clinical progression and survival of patients. SO Ikuerowo MA Kuczyk M Mengel E van der Heyde OB Shittu B Vaske U Jonas S Machtens J Serth, Int J Cancer 2006 119 4 867 874 10.1002/ijc.21869 16557593
26. Methylation of the tumor suppressor gene RASSF1A in human tumors. GP Pfeifer R Dammann, Biochemistry (Mosc) 2005 70 5 576 583 10.1007/s10541-005- 0151-y 15948711
27. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. DG Burbee E Forgacs S Zochbauer-Muller L Shivakumar K Fong B Gao D Randle M Kondo A Virmani S Bader, J Natl Cancer Inst 2001 93 9 691 699 10.1093/jnci/93.9.691 11333291
28. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers. N Yanagawa G Tamura H Oizumi N Kanauchi M Endoh M Sadahiro T Motoyama, Lung Cancer 2007 58 1 131 138 10.1016/j.lungcan.2007.05.011 17606310
29. The relationship between aberrant methylation and survival in non-small-cell lung cancers. S Toyooka M Suzuki R Maruyama KO Toyooka K Tsukuda Y Fukuyama T Iizasa M Aoe H Date T Fujisawa, Br J Cancer 2004 91 4 771 774 15266335
30. Hypermethylation of FHIT as a prognostic marker in nonsmall cell lung carcinoma. R Maruyama K Sugio I Yoshino Y Maehara AF Gazdar, Cancer 2004 100 7 1472 1477 10.1002/cncr.20144 15042681
31. Promoter methylation of RASSF1A, RARbeta and DAPK predict poor prognosis of patients with malignant mesothelioma. JR Fischer U Ohnmacht N Rieger M Zemaitis C Stoffregen M Kostrzewa E Buchholz C Manegold H Lahm, Lung Cancer 2006 54 1 109 116 10.1016/j.lungcan.2006.06.017 16893590
32. Renal-cell carcinoma. HT Cohen FJ McGovern, The New England journal of medicine 2005 353 23 2477 2490 10.1056/NEJMra043172 16339096